Universitätsklinik Essen, Klinik für Hämatologie
Welcome,         Profile    Billing    Logout  
 4 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tresckow, Bastian Von
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/29
MTR², NCT05583071: Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients with PCNSL

Recruiting
2
20
Europe
Tafasitamab, Lenalidomide, Rituximab, Methotrexate
University of Cologne, Incyte Corporation
Non-Hodgkin Lymphoma
02/27
04/27
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
125
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
04/25
09/28
NCT06132737: [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients

Recruiting
1/2
15
Europe
[90Y]Y-PentixaTher, [90Y]Y-PTT
Pentixapharm AG
CNS Lymphoma
09/27
03/28

Download Options